 Patients from 50 to 70 years with de novo AML were randomized to receive ARAC 200 mg m2 d IV x 7 d with either DNR 80 mgm2dx3d arm 1 or IDA 12 mg m2d x 3 d arm 2 or 4 d arm 3. The pts received a failing course of remedial Mitoxantrone involving x 2 and j ARAC 1g m 2 x d x 4 days The pts in CR then received 2 courses of consolidation with, according to initial randomization either DNR 80 mg m2 IDA 12 mg sqm x 1 d 1st treatment or 2 d 2nd treatment and ARAC 1 gsm 2jx x 4 days The pts in CR were then randomized persistent IL2 5 million IU m2 x 5 d month in SC for 12 months or no treatment. 